Abstract 4027: TSN084, a multi-kinase inhibitor, overcomes acquired drug-resistant mutations of cMet, Trks, and Flt3, and displays broad activities against kinase oncotargets Axl, DDRs, and CDK8/19
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-4027
Abstract: Background: Up to date, over 80 small molecule kinase inhibitors have been approved for the treatment of cancers worldwide. This class of targeted therapy benefits millions of patients by improving their disease management and quality… read more here.
Keywords: tsn084; acquired drug; drug resistant; multi kinase ... See more keywords